Literature DB >> 1618251

Formation and excretion of dipyrone metabolites in man.

E Zylber-Katz1, L Granit, M Levy.   

Abstract

The formation and urinary excretion of the dipyrone metabolites, methylaminoantipyrine (MAA), aminoantipyrine (AA), formylaminoantipyrine (FAA) and acetylaminoantipyrine (AAA) were determined following administration of a single oral 1.0 g dose of dipyrone to 12 healthy volunteers. The AAA/AA plasma ratio showed that 3 subjects were slow and 9 were rapid acetylators. Pharmacokinetic parameters were determined separately for each group. A good correlation was found between the plasma and urine AAA/AA ratios. The renal clearance of the four metabolites was similar for both phenotypes. A significant difference in the rate of formation of dipyrone metabolites was found for AA, 0.25 (slow) vs 0.1 ml.min-1.kg-1 (rapid), and for AAA 0.75 (slow) vs 7.53 ml.min-1.kg-1 (rapid). There were comparable differences between slow and rapid acetylators in the AUC and the urinary excretion extrapolated to infinity for AA and AAA. The present results show that the kinetics of dipyrone metabolites in plasma and urine can provide a useful measure of the activity of the enzymes involved in their production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618251     DOI: 10.1007/bf00278482

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Influence of food on the pharmacokinetics of dipyrone.

Authors:  D Flusser; E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

3.  Simultaneous determination of dipyrone metabolites in plasma by high-performance liquid chromatography.

Authors:  E Z Katz; L Granit; D E Drayer; M Levy
Journal:  J Chromatogr       Date:  1984-02-10

4.  Plasma protein binding of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study.

Authors: 
Journal:  JAMA       Date:  1986-10-03       Impact factor: 56.272

6.  [Biopharmaceutical and pharmacokinetic studies on metamizol-14C (Novalgin 14C) given to rats, dogs and men].

Authors:  O Christ; H M Kellner; G Ross; W Rupp; A Schwarz
Journal:  Arzneimittelforschung       Date:  1973-12

Review 7.  Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone).

Authors:  M Volz; H M Kellner
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

8.  Effect of age on the pharmacokinetics of dipyrone.

Authors:  E Zylber-Katz; L Granit; J Stessman; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

10.  Plasma kinetics of dipyrone metabolites in rapid and slow acetylators.

Authors:  M Levy; D Flusser; E Zylber-Katz; L Granit
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  4 in total

1.  The acetylation phenotype: does it contribute to the non-linearity of the metabolite pharmacokinetics of metamizol?

Authors:  N Bacracheva; V Vlahov
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of dipyrone and its metabolites.

Authors:  M Levy; E Zylber-Katz; B Rosenkranz
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

3.  Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine.

Authors:  Fabio Bachmann; Henriette E Meyer Zu Schwabedissen; Urs Duthaler; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2021-11-07       Impact factor: 3.716

4.  Acute Liver Failure in a Patient Treated With Metamizole.

Authors:  Philipp Krisai; Deborah Rudin; David Grünig; Kathrin Scherer; Werner Pichler; Luigi Terracciano; Stephan Krähenbühl
Journal:  Front Pharmacol       Date:  2019-09-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.